Coloplast's stock is down 25% but still overvalued. Learn about CLPBF stock's intrinsic value, growth stats, and if a 20% dip ...

Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

The two stocks have been trending in different directions for months. Here's what that says about the broader market.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Portugal's Estado Novo regime under António de Oliveira Salazar was lauded by some classical liberals for allegedly saving the nation from socialism. However, ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...

Shares plummeted after the announcement, as Wojcicki said she aims to secure the assets of the popular DNA-testing company. Dun & Bradstreet Holdings agreed to be acquired by private equity firm ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...